{"id":395191,"date":"2020-12-08T08:03:36","date_gmt":"2020-12-08T13:03:36","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=395191"},"modified":"2020-12-08T08:03:36","modified_gmt":"2020-12-08T13:03:36","slug":"amolyt-pharma-announces-research-collaboration-with-peptidream","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/amolyt-pharma-announces-research-collaboration-with-peptidream\/","title":{"rendered":"Amolyt Pharma Announces Research Collaboration with PeptiDream"},"content":{"rendered":"

\nAmolyt and PeptiDream will collaborate to optimize and evaluate growth hormone receptor antagonists to select a candidate for clinical development as a potential treatment for acromegaly, a rare endocrine disorder
\n<\/h2>\n
\n

LYON, France and NEWTON, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) — Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, and PeptiDream Inc., a public Kanagawa-based biopharmaceutical company, today announced a research collaboration whereby both companies will work together to test and optimize growth hormone receptor antagonist (GHRA) peptides, with the goal of selecting a candidate for clinical development as a potential treatment for acromegaly, a rare but serious endocrine disorder with significant unmet medical need. Amolyt has also acquired an option to license the identified candidates for future clinical development.<\/p>\n

\u201cWe are pleased to partner with PeptiDream, a leading Japanese biopharmaceutical company with an impressive technology platform for the design of new therapeutic peptides, and whose strategic partners include world class pharmaceutical companies,\u201d stated Thierry Abribat, Ph.D., chief executive officer of Amolyt Pharma. \u201cThe potential expansion of our pipeline into acromegaly, where significant unmet need persists, represents a perfect strategic fit for Amolyt. Given our extensive experience in developing therapeutic peptides, including AZP-3601, our lead clinical candidate for hypoparathyroidism, we will leverage our expertise to bring a promising therapy to acromegaly patients in need.\u201d\u00a0\u00a0\u00a0\u00a0<\/p>\n

Patrick Reid, chief executive officer of PeptiDream Inc., added, \u201cWe believe Amolyt Pharma is the ideal partner to lead the development of our small peptide GHRA platform and to potentially bring an improved treatment paradigm to patients suffering from acromegaly. We are impressed by Amolyt\u2019s therapeutic peptide development capabilities and we are confident in entrusting them with advancing this potentially important asset. We look forward to a mutually beneficial partnership.\u201d<\/p>\n

\n About Acromegaly
<\/strong>Acromegaly is a rare chronic endocrine disorder that is typically caused by an adenoma (benign tumor) of the pituitary gland, and that is characterized by excessive production of growth hormone (GH), resulting in abnormally high levels of insulin-like growth factor-1 (IGF-1). Common features include enlargement of the hands, feet and jaw. Medical complications include cardiovascular disease, cardiomyopathy that can potentially lead to heart failure, impaired glucose tolerance with subsequent development of diabetes, hypogonadism, bone and joint disease, cerebrovascular events, sleep apnea and impaired respiratory function. The mean age of diagnosis is 40-45 years, but it is often diagnosed 4-10 years after onset due to its slow progression. It is estimated that there are 26,000 acromegaly patients in the U.S. and an additional 35,000 in the E.U.<\/p>\n

\n About <\/strong>
\n Amolyt<\/strong>
\n Pharma\u00a0<\/strong>
\n
Amolyt Pharma is building on its team\u2019s established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases. Its portfolio includes AZP-3601, a potential treatment for hypoparathyroidism, and AZP-3404, which is undergoing indication prioritization work. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors. To learn more, visit\u00a0www.amolytpharma.com<\/a>\u00a0or follow us on Twitter at\u00a0@AmolytPharma<\/a>.<\/p>\n

\n At <\/strong>
\n Amolyt<\/strong>
\n :<\/strong>\n <\/p>\n

\n Media: <\/strong>
\n
Cherilyn Cecchini, M.D.
LifeSci Communications
ccecchini@lifescicomms.com<\/a>
+1.646.876.5196<\/p>\n

\n Investors:<\/strong>
\n
Ashley Robinson
LifeSci Advisors, LLC
arr@lifesciadvisors.com<\/a>
+1.617.430.7577<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Amolyt and PeptiDream will collaborate to optimize and evaluate growth hormone receptor antagonists to select a candidate for clinical development as a potential treatment for acromegaly, a rare endocrine disorder LYON, France and NEWTON, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) — Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, and PeptiDream Inc., a public Kanagawa-based biopharmaceutical company, today announced a research collaboration whereby both companies will work together to test and optimize growth hormone receptor antagonist (GHRA) peptides, with the goal of selecting a candidate for clinical development as a potential treatment for acromegaly, a rare but serious endocrine disorder with significant unmet medical need. Amolyt has also acquired an option to … <\/p>\n

Continue reading “Amolyt Pharma Announces Research Collaboration with PeptiDream”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-395191","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAmolyt Pharma Announces Research Collaboration with PeptiDream - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/amolyt-pharma-announces-research-collaboration-with-peptidream\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amolyt Pharma Announces Research Collaboration with PeptiDream - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Amolyt and PeptiDream will collaborate to optimize and evaluate growth hormone receptor antagonists to select a candidate for clinical development as a potential treatment for acromegaly, a rare endocrine disorder LYON, France and NEWTON, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) — Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, and PeptiDream Inc., a public Kanagawa-based biopharmaceutical company, today announced a research collaboration whereby both companies will work together to test and optimize growth hormone receptor antagonist (GHRA) peptides, with the goal of selecting a candidate for clinical development as a potential treatment for acromegaly, a rare but serious endocrine disorder with significant unmet medical need. Amolyt has also acquired an option to … Continue reading "Amolyt Pharma Announces Research Collaboration with PeptiDream"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/amolyt-pharma-announces-research-collaboration-with-peptidream\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-08T13:03:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5ODM5NSMzODYwMjY4IzUwMDA3MjA2NA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amolyt-pharma-announces-research-collaboration-with-peptidream\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amolyt-pharma-announces-research-collaboration-with-peptidream\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Amolyt Pharma Announces Research Collaboration with PeptiDream\",\"datePublished\":\"2020-12-08T13:03:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amolyt-pharma-announces-research-collaboration-with-peptidream\\\/\"},\"wordCount\":537,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amolyt-pharma-announces-research-collaboration-with-peptidream\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5ODM5NSMzODYwMjY4IzUwMDA3MjA2NA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amolyt-pharma-announces-research-collaboration-with-peptidream\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amolyt-pharma-announces-research-collaboration-with-peptidream\\\/\",\"name\":\"Amolyt Pharma Announces Research Collaboration with PeptiDream - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amolyt-pharma-announces-research-collaboration-with-peptidream\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amolyt-pharma-announces-research-collaboration-with-peptidream\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5ODM5NSMzODYwMjY4IzUwMDA3MjA2NA==\",\"datePublished\":\"2020-12-08T13:03:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amolyt-pharma-announces-research-collaboration-with-peptidream\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amolyt-pharma-announces-research-collaboration-with-peptidream\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amolyt-pharma-announces-research-collaboration-with-peptidream\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5ODM5NSMzODYwMjY4IzUwMDA3MjA2NA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5ODM5NSMzODYwMjY4IzUwMDA3MjA2NA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amolyt-pharma-announces-research-collaboration-with-peptidream\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Amolyt Pharma Announces Research Collaboration with PeptiDream\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Amolyt Pharma Announces Research Collaboration with PeptiDream - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/amolyt-pharma-announces-research-collaboration-with-peptidream\/","og_locale":"en_US","og_type":"article","og_title":"Amolyt Pharma Announces Research Collaboration with PeptiDream - Market Newsdesk","og_description":"Amolyt and PeptiDream will collaborate to optimize and evaluate growth hormone receptor antagonists to select a candidate for clinical development as a potential treatment for acromegaly, a rare endocrine disorder LYON, France and NEWTON, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) — Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, and PeptiDream Inc., a public Kanagawa-based biopharmaceutical company, today announced a research collaboration whereby both companies will work together to test and optimize growth hormone receptor antagonist (GHRA) peptides, with the goal of selecting a candidate for clinical development as a potential treatment for acromegaly, a rare but serious endocrine disorder with significant unmet medical need. Amolyt has also acquired an option to … Continue reading \"Amolyt Pharma Announces Research Collaboration with PeptiDream\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/amolyt-pharma-announces-research-collaboration-with-peptidream\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-08T13:03:36+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5ODM5NSMzODYwMjY4IzUwMDA3MjA2NA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amolyt-pharma-announces-research-collaboration-with-peptidream\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amolyt-pharma-announces-research-collaboration-with-peptidream\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Amolyt Pharma Announces Research Collaboration with PeptiDream","datePublished":"2020-12-08T13:03:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amolyt-pharma-announces-research-collaboration-with-peptidream\/"},"wordCount":537,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amolyt-pharma-announces-research-collaboration-with-peptidream\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5ODM5NSMzODYwMjY4IzUwMDA3MjA2NA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amolyt-pharma-announces-research-collaboration-with-peptidream\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/amolyt-pharma-announces-research-collaboration-with-peptidream\/","name":"Amolyt Pharma Announces Research Collaboration with PeptiDream - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amolyt-pharma-announces-research-collaboration-with-peptidream\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amolyt-pharma-announces-research-collaboration-with-peptidream\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5ODM5NSMzODYwMjY4IzUwMDA3MjA2NA==","datePublished":"2020-12-08T13:03:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amolyt-pharma-announces-research-collaboration-with-peptidream\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/amolyt-pharma-announces-research-collaboration-with-peptidream\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amolyt-pharma-announces-research-collaboration-with-peptidream\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5ODM5NSMzODYwMjY4IzUwMDA3MjA2NA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5ODM5NSMzODYwMjY4IzUwMDA3MjA2NA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amolyt-pharma-announces-research-collaboration-with-peptidream\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Amolyt Pharma Announces Research Collaboration with PeptiDream"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/395191","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=395191"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/395191\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=395191"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=395191"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=395191"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}